Chinese General Practice ›› 2022, Vol. 25 ›› Issue (29): 3646-3651.DOI: 10.12114/j.issn.1007-9572.2022.0442
• Article • Previous Articles Next Articles
Received:
2022-04-08
Revised:
2022-07-07
Published:
2022-10-15
Online:
2022-07-21
Contact:
Defeng PAN
About author:
通讯作者:
潘德锋
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0442
项目 | 左心室舒张功能不全组(n=47) | 左心室舒张功能正常组(n=50) | 检验统计量值 | P值 |
---|---|---|---|---|
性别(男/女) | 22/25 | 36/14 | 6.395a | 0.011 |
年龄( | 66.6±8.2 | 59.4±10.4 | 3.775 | <0.001 |
BMI( | 25.6±3.6 | 25.2±3.6 | 0.507 | 0.614 |
糖尿病病史〔n(%)〕 | 32(68.1) | 15(30.0) | 14.07a | <0.001 |
高血压病史〔n(%)〕 | 29(61.7) | 19(38.0) | 5.445a | 0.020 |
吸烟〔n(%)〕 | 11(23.4) | 15(30.0) | 0.537a | 0.464 |
饮酒〔n(%)〕 | 9(19.1) | 8(16.0) | 0.166a | 0.684 |
SBP( | 137±17 | 134±17 | 1.029 | 0.306 |
DBP( | 77±10 | 80±9 | -1.588 | 0.116 |
HR( | 68.55±8.42 | 69.78±9.19 | -0.684 | 0.496 |
GFR( | 103.01±13.33 | 97.88±18.94 | 1.067 | 0.291 |
空腹血糖( | 5.85±1.41 | 6.24±1.79 | -1.111 | 0.270 |
血红蛋白( | 130.00±14.43 | 134.88±15.15 | -1.613 | 0.110 |
白细胞计数( | 6.10±1.89 | 6.38±1.69 | -0.773 | 0.442 |
TC( | 3.86±1.09 | 3.79±0.92 | 0.346 | 0.730 |
TG〔M(P25,P75),mmol/L〕 | 1.49(0.99,2.45) | 1.26(0.87,2.35) | -0.586b | 0.558 |
HDL-C( | 0.97±0.24 | 0.97±0.29 | 0.102 | 0.919 |
LDL-C( | 2.14±0.82 | 2.23±0.78 | -0.562 | 0.576 |
脂蛋白a〔M(P25,P75),mg/L〕 | 237(180,343) | 282(154,375) | -0.477b | 0.634 |
C反应蛋白〔M(P25,P75),mg/L〕 | 1.40(0.70,4.55) | 1.40(0.50,4.50) | -0.586b | 0.558 |
NT-ProBNP〔M(P25,P75),ng/L〕 | 103.00(74.35,402.00) | 87.20(48.60,173.00) | -1.946b | 0.052 |
hsTnT〔M(P25,P75),ng/L〕 | 8.84(6.81,16.54) | 7.80(6.13,15.00) | -0.092b | 0.927 |
Table 1 Comparison of general data between coronary artery disease with left ventricular diastolic function and left ventricular diastolic dysfunction
项目 | 左心室舒张功能不全组(n=47) | 左心室舒张功能正常组(n=50) | 检验统计量值 | P值 |
---|---|---|---|---|
性别(男/女) | 22/25 | 36/14 | 6.395a | 0.011 |
年龄( | 66.6±8.2 | 59.4±10.4 | 3.775 | <0.001 |
BMI( | 25.6±3.6 | 25.2±3.6 | 0.507 | 0.614 |
糖尿病病史〔n(%)〕 | 32(68.1) | 15(30.0) | 14.07a | <0.001 |
高血压病史〔n(%)〕 | 29(61.7) | 19(38.0) | 5.445a | 0.020 |
吸烟〔n(%)〕 | 11(23.4) | 15(30.0) | 0.537a | 0.464 |
饮酒〔n(%)〕 | 9(19.1) | 8(16.0) | 0.166a | 0.684 |
SBP( | 137±17 | 134±17 | 1.029 | 0.306 |
DBP( | 77±10 | 80±9 | -1.588 | 0.116 |
HR( | 68.55±8.42 | 69.78±9.19 | -0.684 | 0.496 |
GFR( | 103.01±13.33 | 97.88±18.94 | 1.067 | 0.291 |
空腹血糖( | 5.85±1.41 | 6.24±1.79 | -1.111 | 0.270 |
血红蛋白( | 130.00±14.43 | 134.88±15.15 | -1.613 | 0.110 |
白细胞计数( | 6.10±1.89 | 6.38±1.69 | -0.773 | 0.442 |
TC( | 3.86±1.09 | 3.79±0.92 | 0.346 | 0.730 |
TG〔M(P25,P75),mmol/L〕 | 1.49(0.99,2.45) | 1.26(0.87,2.35) | -0.586b | 0.558 |
HDL-C( | 0.97±0.24 | 0.97±0.29 | 0.102 | 0.919 |
LDL-C( | 2.14±0.82 | 2.23±0.78 | -0.562 | 0.576 |
脂蛋白a〔M(P25,P75),mg/L〕 | 237(180,343) | 282(154,375) | -0.477b | 0.634 |
C反应蛋白〔M(P25,P75),mg/L〕 | 1.40(0.70,4.55) | 1.40(0.50,4.50) | -0.586b | 0.558 |
NT-ProBNP〔M(P25,P75),ng/L〕 | 103.00(74.35,402.00) | 87.20(48.60,173.00) | -1.946b | 0.052 |
hsTnT〔M(P25,P75),ng/L〕 | 8.84(6.81,16.54) | 7.80(6.13,15.00) | -0.092b | 0.927 |
指标 | 左心室舒张功能不全组(n=47) | 左心室舒张功能正常组(n=50) | Z(t)值 | P值 | |
---|---|---|---|---|---|
SPECT参数 | |||||
LVESV'〔M(P25,P75),ml〕 | 41(32,54) | 38(34,51) | -0.419 | 0.675 | |
LVEDV'〔M(P25,P75),ml〕 | 101(84,117) | 101(87,125) | -0.567 | 0.571 | |
LVEF'( | 56.96±7.46 | 60.36±8.37 | -2.111a | 0.037 | |
PFR〔M(P25,P75),EDC/s〕 | 2.02(1.73,2.48) | 2.68(2.22,3.25) | -4.714 | <0.001 | |
1/3FF〔M(P25,P75),%〕 | 33.0 (25.0,38.0) | 39.0 (30.5,45.3) | -2.748 | 0.006 | |
1/3FR( | 1.75±0.61 | 2.03±0.52 | -2.456a | 0.016 | |
MFR〔M(P25,P75),EDC/s〕 | 1.25(1.03,1.38) | 1.36(1.23,1.54) | -2.769 | 0.006 | |
TPF( | 179.96±34.99 | 148.22±29.48 | 4.842a | <0.001 | |
心导管检查 | |||||
LVESV〔M(P25,P75),ml〕 | 36(29,52) | 36(29,47) | -0.148 | 0.882 | |
LVEDV〔M(P25,P75),ml〕 | 100(87,136) | 104(85,155) | -0.834 | 0.404 | |
LVEF( | 63.51±7.80 | 65.74±10.14 | -1.211a | 0.229 |
Table 2 Comparison of cardiac function parameters obtained by SPECT and cardiac catheterization between the two groups
指标 | 左心室舒张功能不全组(n=47) | 左心室舒张功能正常组(n=50) | Z(t)值 | P值 | |
---|---|---|---|---|---|
SPECT参数 | |||||
LVESV'〔M(P25,P75),ml〕 | 41(32,54) | 38(34,51) | -0.419 | 0.675 | |
LVEDV'〔M(P25,P75),ml〕 | 101(84,117) | 101(87,125) | -0.567 | 0.571 | |
LVEF'( | 56.96±7.46 | 60.36±8.37 | -2.111a | 0.037 | |
PFR〔M(P25,P75),EDC/s〕 | 2.02(1.73,2.48) | 2.68(2.22,3.25) | -4.714 | <0.001 | |
1/3FF〔M(P25,P75),%〕 | 33.0 (25.0,38.0) | 39.0 (30.5,45.3) | -2.748 | 0.006 | |
1/3FR( | 1.75±0.61 | 2.03±0.52 | -2.456a | 0.016 | |
MFR〔M(P25,P75),EDC/s〕 | 1.25(1.03,1.38) | 1.36(1.23,1.54) | -2.769 | 0.006 | |
TPF( | 179.96±34.99 | 148.22±29.48 | 4.842a | <0.001 | |
心导管检查 | |||||
LVESV〔M(P25,P75),ml〕 | 36(29,52) | 36(29,47) | -0.148 | 0.882 | |
LVEDV〔M(P25,P75),ml〕 | 100(87,136) | 104(85,155) | -0.834 | 0.404 | |
LVEF( | 63.51±7.80 | 65.74±10.14 | -1.211a | 0.229 |
参数 | 截断值 | 灵敏度(%) | 特异度(%) | 约登指数 | AUC | 95%CI | P值 |
---|---|---|---|---|---|---|---|
PFR | 2.12 EDC/s | 60 | 84 | 0.436 | 0.778 | (0.687,0.869) | <0.001 |
1/3FF | 37.5% | 75 | 62 | 0.365 | 0.662 | (0.551,0.772) | 0.006 |
1/3FR | 1.75 EDC/s | 57 | 78 | 0.354 | 0.653 | (0.542,0.764) | 0.009 |
MFR | 1.28 EDC/s | 62 | 68 | 0.297 | 0.663 | (0.554,0.772) | 0.006 |
TPF | 185.50 ms | 77 | 70 | 0.466 | 0.755 | (0.658,0.852) | <0.001 |
Table 3 ROC curve analysis of SPECT parameters predicting elevated LVEDP
参数 | 截断值 | 灵敏度(%) | 特异度(%) | 约登指数 | AUC | 95%CI | P值 |
---|---|---|---|---|---|---|---|
PFR | 2.12 EDC/s | 60 | 84 | 0.436 | 0.778 | (0.687,0.869) | <0.001 |
1/3FF | 37.5% | 75 | 62 | 0.365 | 0.662 | (0.551,0.772) | 0.006 |
1/3FR | 1.75 EDC/s | 57 | 78 | 0.354 | 0.653 | (0.542,0.764) | 0.009 |
MFR | 1.28 EDC/s | 62 | 68 | 0.297 | 0.663 | (0.554,0.772) | 0.006 |
TPF | 185.50 ms | 77 | 70 | 0.466 | 0.755 | (0.658,0.852) | <0.001 |
[1] |
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志,2021,36(6):521-545. DOI:10.3969/j.issn.1000-3614.2021.06.001.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志,2018,46(9):680-694. DOI:10.3760/cma.j.issn.0253-3758.2018.09.004.
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
马红,吴伟春,谢荣爱,等. 三维斑点追踪超声心动图评估冠心病患者左心室舒张功能的临床应用价值[J]. 中国循环杂志,2015,30(3):225-229. DOI:10.3969/j.issn.1000-3614.2015.03.007.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
赵慧兰. G-SPECT测定左室容积和射血分数:与左室造影和超声心动图比较[D]. 太原:山西医科大学,2006.
|
[20] |
|
[21] |
|
[22] |
|
[1] | YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377. |
[2] | CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365. |
[3] | LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372. |
[4] | LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360. |
[5] | YAN Haihao, ZHANG Feifei, DANG Yi. Correlation of Remnant Cholesterol with Vulnerable Plaque Characteristics in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2023, 26(26): 3303-3307. |
[6] | ZUMURETI ·Abudukeyimu, MA Yanlin, ZHU Kairui, LIU Fang, LI Xia. Correlation of Early Growth Response 3 and Interleukin 6 Expression Levels with Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(24): 3016-3021. |
[7] | WANG Dan, WANG Jianhui, DONG Jianxiu, CHANG Wenhong, QIN Lu, LIU Qi, CHEN Chen. Effect of an Internet-based Intervention on Motor Behavior in Patients after Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(21): 2603-2608. |
[8] | LIU Jingtao, SU He, QIN Xiaojin, LAN Yunxia, ZHANG Jinzhi. Guidelines on Cardiac Rehabilitation in Patients with Coronary Heart Disease: a Systematic Review [J]. Chinese General Practice, 2023, 26(19): 2323-2331. |
[9] | GAO Yang, WANG Yunxia, GAO Chuanyu. Familial Hypercholesterolemia in 45-year-old and Younger Patients with Acute Coronary Syndrome: Clinical Characteristics and Influencing Factors of Blood Lipid Control Effect [J]. Chinese General Practice, 2023, 26(18): 2232-2237. |
[10] | AN Jingjing, WANG Xiaojuan, DENG Aiyun. Effect of Epicardial Adipose Tissue on In-stent Restenosis after Percutaneous Coronary Intervention: a Review [J]. Chinese General Practice, 2023, 26(09): 1146-1150. |
[11] | DENG Tianhua, HUANG Lin, YOU Zhigang. Advances in Intensified Antithrombotic Therapies in Acute Coronary Syndrome [J]. Chinese General Practice, 2023, 26(09): 1131-1135. |
[12] | CHEN Ying, ZHENG Hui, HE Yu. Association between Nutritional Status and Prognosis in Elderly Patients with Heart Failure with Preserved Ejection Fraction and Coronary Heart Diseases [J]. Chinese General Practice, 2023, 26(03): 335-342. |
[13] | QIN Changyu, CHEN Meixiang, RUAN Zheng, XU Lin. Risk Factors for All-cause Mortality in Patients with Coronary Heart Disease and Hematologic Malignancies [J]. Chinese General Practice, 2022, 25(33): 4130-4138. |
[14] | Anbang LIU, Cheng JIANG, Han YIN, Huan MA, Qingshan GENG. Association between Free Triiodothyronine and Depression in Patients with Coronary Heart Disease [J]. Chinese General Practice, 2022, 25(14): 1707-1712. |
[15] | Zikang FU, Haiying LI, Ping LI. Research Progress of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of T2DM Complicated with Coronary Heart Disease [J]. Chinese General Practice, 2022, 25(12): 1493-1499. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||